Bausch + Lomb (BLCO) announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, the first clinically validated, minimally invasive glaucoma surgery, or MIGS, procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb’s glaucoma portfolio, which features pharmaceutical and surgical approaches. Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time. The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Elios Vision is in the process of pursuing FDA approval for the product. Leerink Partners served as exclusive financial advisor to Elios Vision and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb downgraded to Neutral from Buy at Citi
- Bausch + Lomb downgraded to Equal Weight from Overweight at Morgan Stanley
- Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale
- Bausch + Lomb price target raised to $24 from $20 at Citi
- Bausch + Lomb price target raised to $26 from $23 at Wells Fargo